Day One Biopharmaceuticals Inc (NASDAQ: DAWN) closed the day trading at $15.15 down -2.63% from the previous closing price of $15.56. In other words, the price has decreased by -$0.41 from its previous closing price. On the day, 970315 shares were traded. DAWN stock price reached its highest trading level at $15.82 during the session, while it also had its lowest trading level at $14.95.
Ratios:
For a better understanding of DAWN, let’s look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 12.72 and its Current Ratio is at 12.72. In the meantime, Its Debt-to-Equity ratio is 0.00 whereas as Long-Term Debt/Eq ratio is at 0.00.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, BofA Securities on April 25, 2023, Downgraded its rating to Underperform and sets its target price to $9 from $34 previously.
On February 08, 2023, CapitalOne started tracking the stock assigning a Overweight rating and target price of $40.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Feb 27 ’24 when Blackman Samuel C. sold 20,000 shares for $16.11 per share. The transaction valued at 322,166 led to the insider holds 1,224,662 shares of the business.
Bender Jeremy sold 7,615 shares of DAWN for $116,114 on Feb 16 ’24. The CHIEF EXECUTIVE OFFICER now owns 721,813 shares after completing the transaction at $15.25 per share. On Feb 16 ’24, another insider, Dubow Adam, who serves as the GENERAL COUNSEL of the company, sold 3,242 shares for $15.25 each. As a result, the insider received 49,434 and left with 16,585 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, DAWN now has a Market Capitalization of 1.36B and an Enterprise Value of 995.52M.
Stock Price History:
The Beta on a monthly basis for DAWN is -1.48, which has changed by -16.92% over the last 52 weeks, in comparison to a change of 30.58% over the same period for the S&P500. Over the past 52 weeks, DAWN has reached a high of $19.51, while it has fallen to a 52-week low of $9.67. The 50-Day Moving Average of the stock is 14.97, while the 200-Day Moving Average is calculated to be 13.20.
Shares Statistics:
Over the past 3-months, DAWN traded about 554.40K shares per day on average, while over the past 10 days, DAWN traded about 860.84k shares per day. A total of 87.23M shares are outstanding, with a floating share count of 58.90M. Insiders hold about 32.60% of the company’s shares, while institutions hold 76.21% stake in the company. Shares short for DAWN as of Feb 15, 2024 were 9.72M with a Short Ratio of 17.52, compared to 10.8M on Jan 12, 2024. Therefore, it implies a Short% of Shares Outstanding of 11.14% and a Short% of Float of 17.59%.
Earnings Estimates
Current recommendations for the stock of the company come from 7 analysts. On average, analysts expect EPS of -$0.66 for the current quarter, with a high estimate of -$0.63 and a low estimate of -$0.71, while EPS last year was -$0.59. The consensus estimate for the next quarter is -$0.67, with high estimates of -$0.56 and low estimates of -$0.79.
Analysts are recommending an EPS of between -$2.27 and -$2.89 for the fiscal current year, implying an average EPS of -$2.62. EPS for the following year is -$2.01, with 9 analysts recommending between -$1.21 and -$2.78.
Revenue Estimates
Based on 10 analysts’ estimates, the company’s revenue will be $74.32M in the next fiscal year. The high estimate is $148.9M and the low estimate is $15.1M. The average revenue growth estimate for next year is up 468.60% from the average revenue estimate for this year.
